InvestWiser

Integrum AB Series B

INTEG-BNasdaq StockholmHealthcareMarket value 215 m SEK
8.27SEK +0.4%
last day · Price as of 17 November 2026

The answer first

Does Integrum beat the market?

No, Integrum has not beaten the market over the last year.

Integrum+0.5%Stockholm (OMXSGI)+18.7%
  • The ranking · Quality, value and trend combined

    Better than 37% of Nordic stocks

    • Quality38
    • Value35
    • Trend63

    No. 87 of 195 in healthcare

Max for seven days

Follow Integrum with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 17 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Integrum

From today, at a price of 8.27 SEK. Write why you follow Integrum, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Integrum

Your first answer is free, no account needed.

Do you own Integrum, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Integrum and a few more. Free, no card.

Past year against the exchange and Super Stock
Integrum+0.5%Stockholm (OMXSGI)+18.7%Super Stock+45.9%
14 November 202517 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Integrum has risen 0.5% over the past year, including dividends.
  • Overall, Integrum ranks better than 37% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 88.6%. The price is 91.8% below its peak now.

What do analysts think of Integrum?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

37

Quality, value and trend together. Better than 37% of Nordic stocks.

No. 87 of 195 in healthcare

Quality38
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 149 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.04
  • Asset turnoverSales divided by everything the company owns0.49
  • Return on equityProfit divided by equity−20.4%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value35
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 65 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equity1.2
  • P/SPrice divided by sales2.2
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend63
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 59 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−1.5%
  • 6 months+6.2%
  • 9 months+4.9%
  • 12 months+0.5%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−7.8%
3 years, per year
−37.7%
5 years, per year
−38.3%
Year to date
−23.1%
Largest fall, 3 years
−88.6%
From a peak to the bottom
From the peak now
−91.8%
How far the price is from the peak
Volatility, 1 year
47.3%
How much the price swings over a year
Beta, 1 year
0.31
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Integrum

One fund we follow owns Integrum. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Integrum

Integrum AB Series B is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 33 employees.

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide.

See the full analysis of Integrum.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market